A
Abacavir 436
Abatacept 183
Abdomen 129
Abetalipoproteinemia 516
Acamprosate 831
Acetate, active 69
Acetylcholine 343
Acinar cells, pancreatic 778
Acinar parenchyma, loss of 55f
Acute respiratory distress syndrome 309
Acylglycerol formation 66
Adaptor protein 170
Adeno-associated viral-delivery methods 113
Adipocytokines, proinflammatory 138
Adiposity, visceral 256
Adjuvant aluminum hydroxide 801
Adrenal cortex, glucocorticoids secreting tumor of 126
Adrenal disease 276
Adrenal insufficiency 343
Adrenergic symptoms 229
Adrenocorticotropin 126
Aerobic dancing 580
Aerobic fitness 574
Agranulocytosis 637
abuse 195
moderate 320
dependence, neurobiology of 752
intake
high 624
moderation in 385
use disorders identification test 830
Aldosteronoma 44
Alendronate 486
Aliskiren 360
Alkali therapy 305
Alkalinization reduces oxygen delivery, rapid 308
Allogeneic sources 818
Allograft rejection 772
Alloxan 90
Alopecia areata 276
Alpha-1-antitrypsin 801
Alpha-cell function, dysregulation of 103
Alpha-interferon 44
Alpha-lipoic acid 349
Alprazolam 829
Alteplase 402
Alveolar epithelium, thickening of 429
Alveolar osteitis, prevention of 499
Alzheimer's disease, risk of 553
Ambulatory autonomous care 767
American College of Gastroenterology 516
American College of Obstetricians and Gynecologists 43
American Diabetes Association 41, 161, 179, 194, 212, 213, 228, 231t, 339, 358, 371, 452, 455, 470, 637, 639, 715, 773, 785
procedure 213
Scientific Sessions 769
American Diabetic Retinopathy Study 11
American Gastroenterological Association 516
Amiodarone 516
Amylase 301
Amyotrophy, diabetic 230
Anaerobic exercise 574
Anencephaly 209
Anesthetic agents, types of 743
Angiogenesis 818
Angiography, coronary 386
Angiopoietin-1 819
Angular cheilitis 489
Anion gap metabolic acidosis 300
Anionic trypsinogen 196
Anomaly, types of 209
Anorexia 431
Anoxia accelerates 70
Antagonize 113
Anti-CD5 immunotoxin 800
Anticonvulsants 258
Antidepressants, atypical 828
Antifibrinolytic agents 499
Antifibrotics 524
Anti-hepatitis C virus antibody 515
Anti-insulin receptor antibodies 44
Antiplatelet therapy 413
Antiseptic application 675
Antithymocyte globulin, low dose 801
Antithyroid peroxidase, presence of 264
Antitubercular treatment 448
Antituberculosis drugs, pharmacokinetics of 432
ApoB antisense oligonucleotide 376
Apoplexy 399
Apoptosis 110
Arcuate nucleus 133
Ardha matsyendrasana 581
Ardhakati chakrasana 581
Arm circumference 549
Armanni-Ebstein lesion 80
Arterial blood gas 692
Arterial revascularization therapy study 386
Arteriosclerosis 230
Asberg depression rating scale 828
Ascites, pancreatic 200
Aspartic acid 673
Aspiration pneumonitis, risk of 744
Assessing cardiovascular
adrenergic function 346
autonomic function 345
parasympathetic function 346
Atherogenesis 145
Atherothrombosis 112
Attractive theory 249
Australian Technical Advisory Group on Immunization 455
Autoimmune diabetes, adult-onset 179
Autoimmune endocrine diseases, organ-specific 94
Automate glycemic management 767
Autonomic nerve fibers 465
Autonomic reflexes, quantitative measures of 348
Autophagosome formation, step of 120
Autophosphorylation, rapid 61
Axillo-bifemoral bypass 418
B
Baclofen 831
Bacterial infections, recurrent 282
Basal human growth hormone 187
Basal lamina, pulmonary 429
Basal only insulin regimen 676
Beat-to-beat heart rate variation 346
Beck's anxiety inventory 829
Beck's depression inventory 828
Behavioral activation 829
Behavioral modification 584
Benzene ring, position of 632
Beta-adrenergic agonist 44
adenomas, diagnosis of 292
autoimmunity, evidence of 94
biology 175
damage 90
defect 47
differentiation 172
precedes 817
exhaustion 280
genetic defects of 44
loss of 101
maintenance of mature 172
gene defects 47
hyperplasia 205
mass and function 817
presentation of 89
replacement, sources of 817
transdifferentiation of 101
tumors 294
Betamethasone 736
Bethanechol, use of 507
Bevacizumab 329
Bhujangasana 581
Bihormonal bionic pancreas 767
Bimodal distribution 273
Biobreeding rat 800
BioChaperone Lispro 700
Bionic pancreas 766
Birth weight, high 88
Bisoprolol 349
Bisphosphonates 486
Bleeding, intraperitoneal 776
Blood
amino acid concentration, product of 120
flow, peripheral 135
acute fluctuations of 596
application, self-monitoring of 606
changes, management of 438
cost benefits, self-monitoring of 597
current compliance levels, self-monitoring of 597
elevated 267
limits 606f
maternal 171
rapid lowering of 308
records, self-monitoring of 595
elevated 131
higher 256
monitoring 359
nonpharmacological interventions on 385t
response 345
targets 550b
very low diastolic 232
samples drawn, number of 213
sugar levels 746
transfusion set 729
urea nitrogen 410
B-lymphocytes 55
Body insulin-mediated glucose 62
Body weight, low 284
Body's glucose reserves 768
Bolus insulins 676
Bone 501
deposition 467
disease 483
epidemiology of 483
pathophysiology of 484
risk factors of 484
formation 468
fractures 627
fragmentation of 469f
loss, mechanism of 484
marrow 778
derived stem cells 818
transplant 742
pentosidine levels 485
resorption 467
markers C telopeptide 485
structural alterations 485
turnover markers 486
Bony deformity 469
Bony prominences 468
Bowman's afferent 357
Bowman's layer 339
Bradycardia 345
Bradykinin B2 receptor 354
Branched chain amino acids 121
Breast cancer 249
Breastfeeding 89
Brexpiprazole 828
Brief psychiatric rating scale 831
Bronchial reactivity, reduced 429
Bronchus carcinoma, history of 127
Buprenorphine 831
Bypass angioplasty revascularization investigation 386
C
Calcitriol 840
Canadian National Advisory Committee on Immunization 455
Candesartan 321
Cannabis 831
Capillary nonperfusion 324
Captopril 438
Carbimazole 264
Carboxyl ester lipase 170
Carboxymethyl 143
Carbuncle 531
Cardiac denervation syndrome 343
Cardiac dysfunction 401
Cardiac regenerative therapy 349
Cardiac resynchronization therapy 392
Cardiomyocyte mass 840
Cardiorenal syndrome 393
Cardiorespiratory endurance 574
Cardiovascular disease 140f, 157, 236, 243, 267, 316, 317, 365, 369, 380, 381, 383b, 394, 451, 516, 556, 621, 627, 708, 744, 840, 840fc
clinical manifestations of 389
incidence of 109
kidney pretransplant screening for 773
prevalence of 785
prevention 236
reduce 394fc
Cardiovascular health study 256
Cardiovascular reactions 660
Cardiovascular safety 636
Cardiovascular symptoms 338
Carnosine 354
Casein hydrolysate formula 802
Cassava toxicity 195
Catabolic status 678
Cataract surgery 332
Catatonic behavior 831
Cathepsin B 196
Cationic trypsinogen 196
Caudal regression 209
Cavity, peritoneal 776
Cellular immunity, impaired 448
Cellular mediated autoimmune destruction 45
Central memory T-lymphocytes 801
Cervix 248
Cesarean delivery 49
Cesarean section, planned 744
Charcot deformities, severe 474
Charcot joint 467
Chennai Urban Population Study 797
Chiropathy, diabetic 230
Chlamydia pneumoniae 145
Chlordiazepoxide 831
Chlorpromazine 831
Cholinesterase inhibitor 349
Chromosomal anomalies, screening for 222
Chromosome 44
Chronic diabetes complications, pathophysiology of 111
Chronic obstructive pulmonary disease 552
Chymotrypsinogen C 196
Citric acid cycle 66f
Clinical information delivery systems 824
Clofibrate 636
Clonazepam 829
Clonidine 211
Clot supporting agents 499
Clozapine 831
Cold pressor response 345
Collagen, nonenzymatic glycosylation of 484
Colloid osmotic pressure 309
Coma, hyperglycemic 293t
Combination injectable therapy 677
Compassion fatigue 834
Completely edentulous mandibular arch 500f
Complex therapeutic schedule 826
Congestion, hepatic 290
Contraceptive and intrauterine death, use of 212
Contraction stress test 222
Conus arteriosus defects 209
Cori's cycle 73
Corneal epitheliopathy 319
Corneal microscopy, confocal 338
Corticosteroids 126
Corticotroph adenomas, frontline treatment of 127
Couple coping enhancement training 755
Cramps, abdominal 348
Cuboidal cells, small pale 53f
Cystic changes 430
Cystopathy 344
Cystoscopic-guided transduodenal pancreatic biopsy 775
Cytokine 430
chemotactic 640
synthesis 357
of acute-phase proinflammatory 139
tumor necrosis factor 207
Cytoplasm 60
Cytoplasmic islet cell 92
D
Daclizumab 818
De novo mutations 173
Deep breathing 345
Deep plantar compartments 470
Defective postreceptor insulin signaling 62
Degludec 696
Delta cell 74f
Delusions 831
Denosumab 486
Dense lymphoplasmacytic infiltrate 55f
Dental pulp 818
Deoxyribonucleic acid methylation, modulation of 112
Depressed mood 828
Dermal matrix 476
Desvenlafaxine 828
Detemir 696
Dextrocardia 209
Dextrose normal saline 222
Dhanurasana 581
Diabesity, medical management of 759
Diabetes 25f, 41, 70f, 126b, 157, 365, 399, 410, 431, 400, 444, 490fc, 504, 509, 552, 570t, 756, 757
adult-onset 179t
age of onset of 320
and heart failure 389
and immune-compromised state 552
and infections 142
and malignancy 246
and menopause 242
and polymorphonuclear leukocytes 143
and stress-related depression and anxiety 150
and stroke 400
and vascular smooth muscle cell 411
Association of Nigeria 639
autoimmune 180
type of 54
awareness, education and creation of 806
causative factor for 31
cell therapy for 817
cerebrospinal fluid of 80
chemical induced 545
chronic complications of 229
clinical features of 228
community lifestyle improvement program 810
comprehensive management of 547
consequences of 210
control 538
optimal 471
complications of 317t
duration of 708
during pregnancy, screening for 243f
Electronic Medical Record 797
endemic proportions of 817
exercise therapy in 578
fracture risk assessment in 485
French Study Group 800
global
prevalence of 18
hepatogenous 521
heterogeneous nature of 27
high-risk for development of 94
history of 3
hotspots of world 824
immune mediated 44
inflammation 410
insipidus 276
interventions and complications trial, epidemiology of 109
ketoacidosis 275
kidney disease 551
lifestyle intervention reduced risk of 164
lipoatrophic 44
macrovascular complication of 109
mitochondrial 46
muscle infarction 487
nephropathy, management of 358t
onset of 546
pathophysiology of 227
prediction 89
primary prevention of 806
principles of management of 200
problems in India 797
psychosociology of 824
quality of life scale 755
registers, development of 795
registry 458
renaissance of 5
risk scoring system 808
screening camp 283
severe 80
spectrum of 197f
statin intervention trials in 374t
subtype 179
Technology Society 604
therapy 8t
armamentarium of 246
transient neonatal 44
type 1.5 180
type 2 547b
undiagnosed 24f
with waist-to-hip, type 2 283f
Diabetes care 824
organization of 795
psychosocial aspects of 824
team 785
composition of 787
implementation of 787
Diabetes management
and surgery 742
biopsychosocial model of 584
during travel 749
evidence-base of 588
in multifactorial manner 825
integral part of 548
intrapartum 222
strategies for 796
Diabetes mellitus 27, 65, 73, 78, 108, 123, 126, 149, 175t, 262, 276, 285, 341, 353, 371, 381, 383, 384, 384fc, 391fc, 407, 423, 433, 436, 437, 451, 492, 574, 773, 779, 790, 836
advanced type 2 105
and inflammation 137
and tuberculosis 429
treatment of 432
antituberculosis regimen for 448
approximate frequency of 48fc
bone of 483
complications of 229
epidemiology of 445
type 2 27
etiology of 148
exercise and lifestyle modulation in 574
foods in 568
global trend of 380f
historical developments in type 1 691
hypertension in 365
management
pharmacist-led module for 789
monitoring of 437
musculoskeletal manifestations of 483
noninsulin dependent 430
nutrition management of 556
ongoing medications for 486
oral complications of 489
oral manifestations of 489t
pathogenesis of 426b
pathophysiology and genetics 85
post-transplantation 49
presence of 423
slowly progressive
insulin-dependent 180
stress-induced 430
type 1 9, 18, 34, 43, 46t, 85, 88t, 92t, 93t, 95, 121, 169, 186, 208, 217f, 246, 274t, 280, 281t, 323, 353, 399, 451, 545, 559fc, 576b, 597t, 605f, 653, 692fc, 692t, 699t, 750, 777, 786, 800
clinical presentation 274
differential diagnosis 277
epidemiology 273
genetic disorders 276
in special populations 275
risk factors 273
type 2 10, 18, 44, 46t, 75, 104, 140f, 159, 209, 217f, 255f, 258b, 281t, 282t, 283f, 284b, 285b, 285t, 313, 353, 371t, 391t, 394fc, 483, 509, 577, 598t, 605f, 622, 640, 648, 679t, 680, 692t, 710, 759, 785, 805, 817, 820t, 821t
clinical features 282
complications of 283
differential diagnosis 284
epidemiology 280
management of 256
types of 247
varieties of 57
clinical presentation 342
course of disease 342
epidemiology of 341
imaging techniques 347
pathogenesis 341
perioperative management 349
therapeutic approaches 348
care 340t
classification of 472
severe 470f
syndrome 463
classification 465
diagnosis 470
epidemiology 464
management 471
pathogenesis 465
prevention 474
socioeconomics 464
ischemic 475
management 479
pathways of 468fc
prevention 479
diagnostic criteria for 302t
Diabetic microvascular complications, risk of 108
classification of 336
complications of 339
diagnosis 338
epidemiological aspects 335
prevention of 339
preventive measures 339
progression of 339
risk factors 335
screening methods 315
symptoms of 337
treatment of 339
types of 336b
Diabetic pregnancy, effects of 208
candesartan trials 321
combination of therapies 329
epidemiology 318
grading of 319
management of 324
pathogenesis of 321
progression of 321
risk factors of 320
screening protocols for 323
Diabetogenic drugs 285
Diazepam 831
Diazoxide 44
Dietary
amino acids, storage of 115
calcium, low 836
fat, sources of 563
management 548
measures 199
potassium 385
enhanced intake of 385
protein intake 359
sodium 385
reduced intake of 385
toxins 195
Digestive enzyme 76
Digital subtraction angiography 471
Dilantin 44
Diltiazem 211
Dimerization 141
Disk, neovascularization of 319
Disulfiram 831
Dizygotic twin 274
Dizziness 644
Dobutamine 393
Docosahexaenoic acid 371
Domperidone, use of 506
Dorsal motor nucleus 133
Dry socket-alveolar osteitis 497
management 498
onset and duration 498
pathogenesis 498
sign 498
symptoms 498
treatment 499
Dual hormone 767
Dual-chamber infusion pump 767
Duloxetine 828
Duodenum 200
Dysfunctional alpha cells 103
Dysmetabolic syndrome 267
Dyspareunia 338
Dysphagia 338
Dysplasia, pancreatic 173
Dyspnea 391
Dysrhythmias 209
E
Early treatment diabetic retinopathy study 318
Economical test 214
Edmonton protocol 818
Education Treatment Program, component of 602fc
Effector T cells natural killer 100
E-health technologies 571
Eicosapentaenoic acid 371
Electrocardiogram 390
Electrolytes 746
Electrophysiology 338
Embden-Meyerhof pathway 69
Emergency life-saving procedures 734
Emotional disorders 554
Emphysema 231
Employment decisions 756
End diastolic velocity 538
Endocrine
abnormalities 48b
cell
pancreatic 53
subsets 54
diseases 285
affecting glucose regulation 278
disturbances 241
function 199
neoplasia type 1, multiple 127
symptoms 338
Endometrium 246
Endomysial antibody 275
Endoneuronal ischemia 342
Endophthalmitis 440
Endoplasmic reticulum 100
Endothelial function 423
Endotoxemia, metabolic 255
Energy, loss of 828
Enfuvirtide 436
Enteral feeding 735
Enteral nutrition 746
Epalrestat 349
Epidermal growth factor 475
Epidermophyton 531
Epigenetic therapy 113
Erythematous crusting lesion 493
Erythrasma 424
Erythromycin, use of 506
Erythropoietin 348
Escherichia coli 9
Esophageal enteropathy 344
Esophagus, adenocarcinoma of 248
Ethambutol 432
Etizolam 829
Etravirine 436
Euglycemic clamp 120
Evogliptin 643
Excessive fluids, use of 309
Exendin-based therapies 684
Extra mitochondrial isocitric acid dehydrogenase system 72
Extrahepatic tissues, oxidation in 72f
Extravascular fluid depletion 297
F
Fagerström test 830
Fatal cardiovascular disease 34
Fatigue 391
abundance of 75
biosynthesis of 72
dissemination of 100
metabolism 437
disorder of 342
oxidation 103
polyunsaturated 269
synthesis 65
Fatty liver 138
Fecal urgency 258
Fed state hypoglycemia 289
Femorofemoral bypass 418
Ferritin 515
Fetal
activity, maternal assessment of 222
beta-cells, hypertrophic 217
biophysical profile 222
cord 818
development, effects of maternal fuels on 212
evaluation 221
growth retardation 211
heart rate monitoring, antepartum 221
hyperinsulinemia 208f
implications 712
loss 711
macrosomia 216
nutrient transport, maternal 208f
Fever, mild-to-moderate 821
Fibric acid derivatives 372
clinical features 197
complications 200
diagnosis 198
epidemiology 194
etiological hypotheses of 195
etiopathogenesis 195
familial aggregation of 196
management 199
pathology 196
Fibroma, diabetic irritational 496f
Fidarestat 349
Finnish Diabetes Prevention Study 810
Finnish Dietary Intervention Trial for Prevention of Type 1 Diabetes 802
Fistula, pancreatic 200
Flank pain 228
Flash glucose monitoring 615t
Flavin adenine dinucleotide 356
Fludrocortisone acetate 348
Fluid therapy 303
Fluorescein angiography 324
Fluorodeoxyglucose-positron emission tomography 248
Fluoroquinolones 44
Flupenthixol 831
Flutamide 131
Fluvastatin 370
Follicle-stimulating hormone 191
Foodstuffs, oxidation of 67
Foot
and ankle, joints of 467
care 339
advice 481
team, treatment of 475
infection 470
recurrent 480
pulse 479
majority of 465
primary healing of 464f
Forxiga 763
Frank diabetes mellitus, prevalence of 434
FRAX scoring 488
Free oxygen radicals, generation of 209
Freinkel hypothesis 212f
Frozen shoulder 487
Fructosamine, serum 213
Fuel metabolism, physiology of 575
Functional mutations, heterozygous loss of 173
Furunculosis 531
G
Gadolinium enhancement 127
Galectin attenuate insulin signaling 100
Galega officinalis 9
Gangliocytoma, hypothalamic 127
Gangrene 11
Gaseous exchange 475
Gastritis, atrophic 94
Gastrointestinal
autonomic neuropathy 344
complications, clinical symptoms of 505
glucose absorption 263
involvement 552
peptide hormones, number of 74
reactions 660
surgeries 746
pathophysiology of 504
therapeutic system 634
tract 504
Gastropathy, diabetic 211
Gemigliptin 643
Genes, proinflammatory 112
Genotype, association of 480
Germline mutations 127
Gestational diabetes mellitus 42, 44, 48, 49, 54, 56, 171, 205, 211, 215, 219t, 222, 223, 241, 280, 323, 545, 578, 600, 657, 710, 712, 712f, 713t, 715-717, 717fc, 718, 722
etiology of 212b
epidemiology 711
risk factors 711
maternal 208f
mild 716
pathogenesis of 212b
pathophysiology of 207
postpartum management of 43
prevalence rates 711
rates of 240
Gingival biopsy specimens, microscopic examination of 492
Gingival disease 433
Glinides 10
Glitazars, chemical structures of 662f
Glomerulosclerosis, nodular 357
Glossitis, benign migratory 497f
antagonist 106
blocks glycolysis 75
functions 103
secreting tumors 278
secretion
and alpha-cell function 103
excessive 103
failure of 104
stimulation test 800
suppression, establishing failure of 104
Glucagonemia 640
Glucagon-stimulated C-peptide 821
cause centripetal redistribution 149
effects of 127f
excess 126
pathological role of 126
hormone, endogenous 126
synthetic 126
Glucokinase 175
Glucolipotoxicity 255
Gluconeogenic substrate 76
dehydrogenase 322
absorption 76
concentrations 219
control 764t
entry of 69
optimize 486
counter-regulation 290
dependent insulinotropic
polypeptide 74
entry 62
fasting 157
fatty acid cycle 70f
abnormalities of 521
classification of 41
diagnosis of 41
hypothesis 108
in isolated β-cell 74f
diagnosis of 263
levels
fluctuation 263
high 103
lowering medications 703
effects of 760
management, intrapartum 737
membrane transport of 72
optimizing 837
phosphorylation 171
processes of 70
rate of 70
production 510fc
serum 299
stimulated insulin secretion 212
synthesis 133
target for 231t
clinical implications of impaired 160
development of impaired 161
etiology of impaired 159
impaired 25f, 27, 42, 126, 128, 140, 141, 157, 160, 209, 215, 274, 381, 436, 437, 622, 627, 716, 805
instability of impaired 158
isolated impaired 807
pathogenesis of impaired 159
regulation of abnormal 809
stage of impaired 280
test 446
toxicity 148
translocation of 818
utilization, peripheral 262
Glucosuria 42
Glucotoxicity 101
Glutathione, reduced 110
Gluten rich food 95
for surgery, importance of 742
level of 607
monitoring 220
optimizing 348
stabilization of 339
stable 734
targets for 695t
Glycemic load 562
Glycemic monitoring, consensus guidelines for 603
Glycemic optimization, treatment for 821
Glycemic status 708
Glycemic targets 717
Glyceraldehyde-3-phosphate dehydrogenase, activity of 322
Glycogenesis 510
Glyconeogenesis, regulation of 68f
Glycoxidation products 143
Goiters, multinodular 264
Golgi apparatus 669
Gonadal failure 94
Great toe, phalanges first metatarsal head of 471f
Group B streptococcal bacteremia 440
Growth
factor
alpha, transforming 322
beta, transforming 354
serum insulin like 127
insulin-like growth factor 128
stimulation 818
Guardian link transmitter 769
Gut-brain-adipose tissue 255
H
Hallucinations 831
Haloperidol 831
Hartmann's solution 304
Healing 464f
Heart 625
atherosclerotic 283
hospitalization for 165
management of 391
mechanism of 389
symptomatic 392fc
outcomes prevention evaluation 165
response 346
variation 345
transplant 49
Helicobacter pylori 145
Hematologic reactions 660
Hemodynamic mechanisms 354
Hemoglobinopathies 42
Hemoptysis, greater tendency of 431
Hemorrhage
intracerebral 399
intraretinal 319
recurrent vitreous 331
subarachnoid 399
symptomatic intracranial 401
Hepatic cell plasma membrane 75
Hepatic disease, severe 624
Hepatic fibrosis, pathogenesis of 518
Hepatic lipase 369
Hepatic transplant 425f
Hepatitis 509
A vaccinations 517
autoimmune 522
B
and diabetes 457
surface antigen 515
severe 290
viral 520
Hepatobiliary reactions 660
Hepatotoxicity, minimal evidence of 519
Heterozygous mutations 171
Hexokinase, inhibition of 70
Hexosamine pathway 357
Hexose monophosphate shunt pathway 67
Hexosediphosphatase 73
High blood pressure education program 786
High-intensity statin therapy 370t
Histocompatibility complex, major 181
Homeostasis 133
Human
body regulates energy 133
brain, sole fuel for 73
diet, integral part of 562
growth hormone 188
placental lactogen 205
Huntington chorea 44
Hybrid closed-loop system 769
Hydramnios 49
Hydrocephalus 209
Hydroxychloroquine 659
adverse drug reactions 660
approval status 660
novel mechanism of action 660
reduction in inflammation 660
Hygiene hypothesis 89
Hyperactivity 401
Hypercholesterolemia 80
Hyperglucagonemia 103
acute 743
burden of 727
complications of 595
context of 104
control 703
of maternal 210
correction of severe 694
degree of 144
development of 115
during pregnancy 25f
hyperinsulinemia hypothesis 212
in acromegaly 128fc
in hospital management of 727
induced tissue damage 109
maternal 712fc
measure of 446
mechanisms of 130fc
amelioration of 818
monitoring of 595
new onset 434
persistent 501
prevalence of 742
primary cause of 41
reversing 778
stable fasting 171
Hyperglycemic crises, association of 297
Hyperkalemia 209
Hyperosmotic nonketotic coma 306
Hyperostosis, diffuse idiopathic skeletal 483
Hypersomnia 828
Hypocalcemia 210
Hypochlorhydria 130
autoimmune 294
causes of 750
clinical features 291
complications 292
concern 708
course and prognosis 292
differential diagnosis 292
etiology 289
increased risk of 112
insulin induced 752
ketotic 290
lesser chances of 696
life-threatening 766
management 293
neonatal 294
one hand 553
postprandial 291
prevent 294
risk of 112
signs of 291t
symptoms of 752
treatment of 216
unawareness 293
Hypogonadism 553
Hypokalemia 308
Hyposalivation 494
Hypothalamic disorders 262
Hypothesis 144
Hypothetical islet secretion 6
Hypoxia 342
I
Icodextrin 604
Immunofluorescence 92
Immunogenetics 186
Immunoglobulin 423
Immunohistochemical staining 338
Immunomodulation 818
Implant placement 500f
Indian Council of Medical Research Guidance 838
Indian Diabetes Prevention Study 797
Indian Pregestational Diabetes Mellitus 721
Indian Scenario of Immunization 457
Indian Standards Organization 604
Inflammatory cells, recruitment of 323
Inflammatory pathways, activation of 100
Injury, hepatocellular 513
Insomnia 828
absorption 675
accelerates glucose uptake 72
action
genetic defects in 44
integrative physiology of 116
mechanisms of 117f
molecular mechanism of 59
administration, routes of 671
amounts of 695
first long-acting 8
antibodies, development of 86
correctional 732
crystallization techniques 8
consequences of severe 79f
presence of 62
severe 70f
degludec 674
degradation 212
delivery of 767
treatment for 11
detemir 722
dosage, adjustment of 750
effects of 120
endogenous 92
era 6
first clinical use of 8
gene mutation 173
hypoglycemia, adjust 680
indications of 678
infusion
preparation for 728t
protocol 728
systemic 120
inhaled 671
in hospital 732
injection sites 698
titration and correction doses 697
sites 675f
insensitive tissues 212
intermediate-acting 696
intra-islet 104f
intravenous fluid 222t
lispro 721
lower concentrations of 255
metabolism effects of 74fc
molecule, structure 62
action relationship of 59
multiple-dose 601
nutritional 732
omission 755
pen, set of 749
producing cells 818
pump 696
therapy 601
mutations 285
regimens 676
release 74f
background of 817
causes of 434b
intervention after stroke 627
parameters 149
pathways 837
prevalence of 381
stages of 281
type A 44
underlying 162
response
adequate 215
first phase 207f
responsiveness 60
role of 112
inhibition of 126
poor 426
secretory defect, progressive 545
during gestation 207f
maternal 205
sensitizers 621
sensitizing peroxisome proliferator 250
cascade 207
sources of 221
specific cell surface receptors 63
stimulated protein synthesis 119
stimulates glucose 69
structure 670f
and synthesis 669
synthesis, modulator of 174
complications of 681
total daily dose of 733t
transport 117
types of 672t
Intensity, moderate 370t
Intensive care unit 746
Interferon-gamma interferon gamma, inhibition of 89
International Diabetes Federation 17, 27, 28t, 29f, 158, 232, 240, 241, 267, 268, 451, 595, 639, 703, 710, 785, 794, 795, 805
Guidelines 601
International Expert Committee 42
International Federation of Gynecology and Obstetrics 711
Interpersonal psychotherapy 829
Interphalangeal joints 468
Intestinal microbes 513
Intestinal mucosal barrier function 255
Intra-arterial mechanical thrombolysis 402
Intra-arterial thrombolysis 402
Intracellular bactericidal activity 779
Intracellular insulin signalling, impaired 212
Intracellular metabolic pathway 66f
Intracellular myoinositol, diffusion of 209
Intracellular protein, breakdown of 304
Intracellular signaling pathways 118
Intraepidermal bullae 228
Intraocular pressure 327
Intrapancreatic cells 778
Intrapenile injections 540
Intrauterine death 217
Intravenous radio contrast material, use of 624
Intravenous tissue plasminogen activator 402
Intravitreal elimination half-life 327
Intravitreal injection treatment paradigms 328
Intrinsic minus foot 467
Ipragliflozin 524
Irritation fibromas 496
Ischemic foot, treatment of 413
Islet autoantibodies, measurement of 93
Islet cell 771
presence of 180
prevalence of 187t
secrete glucagon 54
adverse effects 776
developments and research in field 776
limitations 776
Islet donors 776
Islet function 821
Isocarboxazid 828
Isoleucine 121
Isometric resistance 385
Isophane 696
K
Kapalbhati 581
Karnal glucocoper 833f
Kerala Diabetes Prevention Program 810
Ketoacids 300
Ketoanion metabolism 305
Ketosis 510f
Ketotic smell 275
disease 358
end-stage 771
outcomes quality initiative 772
pathology of 357
injury, acute 746
living-donor 771
pancreas transplantation 773
post-transplantation care 772
pre-transplant evaluation 772
standard-criteria donor 771
transplantation 771
benefits of 771
living donor 771
Kimmelstiel Wilson nodules 357
Klebsiella infections 440
Knee 483
Kussmaul breathing 298
L
Lactate dehydrogenase, action of 511
Lactic acidosis 623
Lacunar infarcts 399
Lamivudine 436
Lansoprazole 183
Laparotomy 776
Larva therapy 476
L-asparaginase 278
Laurence-Moon-Bardet-Biedl syndrome 44
Lecithin sphingomyelin 210
Left atrial volume index 390
Leprechaunism 44
Lethal malformations, occurrence of 216
Leukocytosis 301
Levamisole 496
Levomilnacipran 828
Levosimendan 393
Levothyroxine 264
Libido, loss of 338
Limb amputation 464t
Lipemia 80
Lipid 301
lowering agents 109
pharmacology of 372t
lowering
drugs 113
therapy 324
modifying drugs 374
peroxides, levels of 110
profile
abnormal 131
atherogenic 256
target for 231t
Lipogenesis 73
Lipolysis, excessive 77
Lipotoxicity, molecular mechanism of 140
abscess 440
biopsy, role of 515
cirrhosis 744
cytosol 510
damage 439
acquired 290
alcoholic 516
association of 509
complications of 520
frequency of 519
progression of viral 428
treatment of 522
during fasting conditions 510fc
failure 258
function tests, elevated 776
oxidation in 69f
phosphorylase 290
role of 509
secretory proteins, synthesis rate of 121
transplant 49
Loci 88
Long-chain fatty acids 66
Lorazepam 831
Lovastatin 370
Low calorie diet, consumption of 760
Lower extremity, pulses of 418
Lung
carcinoid tumor of 127
diseases, chronic 552
maturity, amniocentesis for 221
small cell carcinoma 126
transplant 49
Luteinizing hormone 191
Lysine 143
M
Macroalbuminuria 354
Macroangiopathy, peripheral 428
Macroglial cells, major class of 135
Macular degeneration, age-related 323
Macular optical coherence tomography 324
Madras Diabetes Research Foundation 174
Magnesium 218
Malate dehydrogenase 72
Malic enzyme 72
Malnutrition-related diabetes mellitus 186
clinical features 188
complications 191
diagnostic criteria 188
etiopathogenesis 187
investigation 189
management 190
Malonyl-CoA stimulates, level of 79
Mammalian cells 65
Mammary artery, internal 387
Mandibular arch, implants in 500f
Mania, precipitation of 259
Mannitol 567
Mantoux test 433
Marrow adiposity 484
Matrix metalloproteinases 100
Matsyasana 581
Meal-priming insulin bolus 768
Mean plasma glucose, maintenance of 220
Meditation 581
Mediterranean diet 270
Menorrhagia 283
Metabolic cum vascular disorder 179
Metabolic disease, chronic 483
Metabolic recovery, stage of 693
Metabolize pyruvate 65
Meta-iodobenzylguanidine 347
Metastatic cancer, uncontrolled 231
Metatarsophalangeal joints 467
Metformin 112, 131, 172, 200, 233, 244, 250, 393, 439, 517, 621, 624b, 624t, 694, 700, 704, 706, 719, 733, 735, 754, 760, 761
actions of 622f
adverse effects 623
continuation of 221
indications and dosage 624
mechanism of action 622
metabolic effects of 622t
pharmacokinetics 623
precautions 624b
and contraindications 623
therapy 623
use of 623
Methadone 831
Methicillin-resistant Staphylococcus aureus 476
Methotrexate 516
Methylhistidine excretion 122
Metoprolol 349
MICA gene, sequence determination of 187
Michaelis constant 70
Microaneurysms, presence of 319
Microangiopathy 428
Microbiota-driven inflammation, state of 255
Microdrip set 729
Micronized 221
Micronutrients 566
Microsporum 531
Microvascular and macrovascular disruption 415
Midodrine 348
Milk exchange 568
Mindful meditation 830
Mineralocorticoid receptor antagonists 391
Mini-mental state exam 236
Mipomersen 376
Mirtazapine 828
Mitochondria, myocardial 634
Mitochondrial
deoxyribonucleic acid 44
damage 109
mutations 285
dysfunction 110
electron transport chain 356
malate transporting system 72
overproduction 109
Mixed meal tolerance test 800
Monoamine oxidase inhibitors 828
Monogenic disorder 170
Monogenic gene panel 175
Monounsaturated fatty acids 269
Monozygotic twin 274
Montgomery 828
Motor nerve functions 821
Motor neuropathy leads 467
Moxifloxacin 432
Mucormycosis 779
Mucous membrane pemphigoid 491
Multi-vessel disease 387
abnormalities 483
cramps 284
infarction, diabetic 483
lipid accumulation 434
mass, loss of 121
tension 829
wasting of 338
Muscular atrophy, evidence of 486
Muscular contraction 70
Muscular fitness 574
Mycobacteria 431
Myelocele 209
Myofibrillar protein breakdown, index of 122
Myoinositol, metabolism of 80
Myonecrosis, diabetic 487
Myosin 423
Myotonic dystrophy 44
N
Nail deformities 470
National Diabetes Surveillance System 253
National Glycohemoglobin Standardization Program 12
National Health Department of Seriousness of Diabetic Foot Problem 463
National Institute of Clinical Excellence 323
National Institute of Diabetes and Digestive and Kidney Diseases 776
National Kidney Foundation 358
National Pancreas Allocation System 773
National Urban Diabetes Survey 254
Necrobiosis lipoidica diabeticorum 528
Necrosis factor-kappa-B 112
Nefazodone 828
Negative pressure wound therapy 475
Neoplasia 44
Neural crest-derived chromaffin cells 129
Neural stem cells, intravitreal injection of 821
Neuralgia, postherpetic 456
Neuroendocrine cells, embryological origin of 53
Neuroendocrinological pathways, abnormalities of 149
Neurological disorders 277
Neurological examination like neuropathy symptoms score 338
Neuronal nitric oxide formation, reduced 537
Neuro-osteoarthropathic joint 468
Neuropathic cachexia 228
Neuropathic plantar ulcer 465f
Neuropeptides 640
Neurosensory disorders 497
Neutropenia 776
Nevirapine 436
New York Heart Association 395
Nocturia 484
activity score 516
and steatohepatitis 511
associations 512
clinical features 514
diagnosis 514
differential diagnosis 516
laboratory findings 514
management 516
mortality 516
pathogenesis 512
prevalence 511
etiology of 623
Non-clostridial gas gangrene 424
Nondihydropyridine calcium channel blocker 359
Nonenzymatic glycation reactions 497
Non-exercise activity thermogenesis 581
Noninsulin injectable therapies 683
Nonnucleoside reverse transcriptase inhibitors 436
Nonoxidative leucine disposal 121
Nonstress test 222
Nonsulfonylurea secretagogues 10
Nonsurgical periodontal therapy 490
Nonulcer pathologies 470
Noonan syndrome 277
Normoglycemia 274
Novorapid 220
N-terminal pro-brain natriuretic peptides, elevated 643
Nuclear factor-kappa beta ligand 467
Nucleic acid, locked 113
Nutrition
and health awareness 806
in surgery 746
intervention 556
parenteral 516
proximate principles of 65
recommendations 557
therapy, goals of 549b
Nystatin 494
O
criteria for 557t
development of 269
dyslipidemia syndrome 267
early stages of 141
evaluation of 548
incidence 253
insulin resistance-diabetes 759
major causes of 133
management of 257
new onset of 698
persistence visceral 127
points 255
visceral 149
Obeticholic acid 518
Obstetric surgery 744
Obstruction, mechanical 200
Ocular muscle palsies 319
Olanzapine 831
Onychomycosis 470
Optimal chronic care model 794b
Oral anticoagulants, newer 403
Oral ulcers, higher prevalence for 496
Osteoarthropathy, diabetic 487
Osteocalcin 485
Osteoprotegerin 490f
Otelixizumab 800
Otitis externa, malignant 424
Ovarian failure, primary 94
Oxalate nephropathy 258
Oxazepam 831
Oximetry, transcutaneous 415
P
Padhastasana 581
Paliperidone 831
Palpitations 229
after kidney transplantation 774
carcinoid tumor of 127
carcinoma of 249
duodenum homeobox-1 777
endocrine 103
pancreatic beta cell of 85
pathology of 53
Pancreatic diabetes, causes of 194b
Pancreatic ducts 778
Pancreatic enzyme supplementation 200
Pancreatic inflammation, role for 101
Pancreatic polypeptide 54
Pancreatozymin 190t
Papaverine 540
Paracrine 105
Paraesthesias 259
Parasitic infestations 100
Parasympathetic system, assessment of 345
Parathyroidectomy 131
Paresthesias 348
Parivrtta trikonasana 581
Pedersen hypothesis 212f
Pegvisomant 128
Pelvis 129
Pen injectors 220
Pentosidine 485
Pentoxifylline inhibits 518
Peripheral fat, loss of 436
clinical
evaluation 408
presentation 408
diagnosis 408
etiopathogenesis 406
evaluation of 772
imaging studies 415
investigations 415
laboratory studies 410
management 416
medical management 411
mortality risk 406
noninvasive evaluation for 409
pathophysiology 406
prevalence and incidence 405
prognosis 418
risk factors 407
structured exercise therapy 411
treatment of symptomatic 413
Peritoneal dialysis solution 604
Permissive hypertension, concept of 402
Petrosal sinus sampling, bilateral inferior 127
Phagocytes, activated mononuclear 141
Phenelzine 828
Phentolamine 540
Phosphatidylinositol-3-kinase 61
Phosphoenolpyruvate carboxykinase 73
Phosphoglycerokinase 73
Piloerection 348
Pinprick sensation 470
Pitavastatin 370
Placental chorionic somatomammotropin 205
Plantar
assessment, sites of 315f
callus, growth of 467
metatarsal pads 472
quantitative measurement of 466
ulcers 467
xerosis 467
Plasma 190
C-peptide levels 281
glucagon secretion 105
fasting, measure of 43
insulin, basal level of 77
iron 515
ketones 190
after epinephrine 190
osmolality 300
triglycerides 70f
Plastazote 474
Pneumococcal vaccines 452
Polioviruses 89
Polyclonal anti-T-cell antibodies thymoglobulin 774
Polycythemia 210
Polyendocrine syndrome, autoimmune 94
Polyethylene foam 474
Polyhydramnios 211
Polymorphonuclear leukocytes, action of 143
Polypeptide, pancreatic 76
Porphyria 44
Portal vein 200
Postpartum, vicious cycle of 241
Post-translational histone modifications 111
Potent phagocytic stimulus 100
Potent protein anabolic hormone 115
Prader-Willi syndrome 44
Prandial glucose regulators 638
Pravastatin 370
Prazosin 211
Preadipocytes, insulin stimulates differentiation of 255
Prednisone 774
Pre-eclampsia, increased risk of 49
Pregnancy
acute fatty liver of 516
insulin requirement of 217
prediabetes in 710
second trimester of 221
third trimester of 221
Probucol 518
Prolyl endopeptidase 640
Propranolol 290
Prosthesis, implant supported partial 500f
Prostoglandin analogs 349
Protective pain sensation, loss of 467
degradation 743
energy malnutrition 186
homeostasis 123
kinase 119b
loss, rapid 115
normal metabolism of 115
role in 67
tyrosine phosphatase 88
Pseudocyst 200
Pseudohyperchloremia 301
Pseudomonas aeruginosa 228
Psychiatric comorbidity and diabetes 826
Psychological disorders, prevalence of 554
Psychomotor agitation 828
Psychosocial disorders 554
Puberty 273
Pump failure 749
Pyelonephritis 424
Pyoderma 528
Pyogenic infections 547
Pyrazinamide 432
Pyridostigmine bromide 349
Pyridoxine 432
R
Rabbit thymoglobulin 773
Rabson-Mendenhall syndrome 44
Radiobinding assay 92
Radioimmunoassay 92
Raloxifene 486
Raltegravir 436
Ramipril 349
Randomized controlled trials 809
Ranibizumab 329
Rectal sensations, impaired 344
Regular macrodrip set 729
Renal function tests 746
Renal parenchymal cells 821
Renal transplant 49
Respiratory distress syndrome 210
Respiratory system 53
Restore oxygen delivery 323
Retardation, growth of 121
Retinal capillaries, leak out of 324
Retinal vein occlusion 319
Revascularization procedures, indications of 415
Reye syndrome 516
Rhabdomyolysis 309
Rhizopus oryzae 439
Rhomboid glossitis 493
Ribose-5-phosphate 65
Rifampin 430
Ringer's lactate 304
Risedronate 486
Risperidone 831
Ritonavir 436
Rituximab 183
Root canal treatment 493
Rosuvastatin 370
Rubella 88
Rubeosis iridis 319
Rubeotic glaucoma 331
Ryle's tube 739
S
Saint Vincent declaration 795
Salivary dysfunction 489
Salivation test 347
Salmonella enteritidis 440
Saquinavir 436
Sarvangasana 581
Scleredema diabeticorum 529
Seizure disorders 259
Selected proinflammatory cytokine gene polymorphisms 141t
Selective estrogen receptor modulator 486
Selective recurrent beta-cell destruction 92
Sensation 479
Sensory nerve functions 821
Sensory peripheral neuropathy 779
Serine-threonine kinases, activation of 255
Serotonin-norepinephrine reuptake inhibitors 828
Serum alpha-fetoprotein, maternal 222
Serum beta-hydroxybutyrate, direct measurement of 299
Serum protease inhibitor Kazal type-1 196
Shock, cardiogenic 393
Sialoadenosis 494
Sialoglycoprotein 92
Sight-threatening disease 318
Signal transducer, activation of 248
Sildenafil 539
Simvastatin 370
Single donor islets, use of 775
Sirolimus 818
Skeletal muscle 127f
cells 634
mass
decrease of 483
loss of 115
protein
anabolism 118
synthesis 118
tissue including 120
Skin 644
and mucosal colonization 779
diseases associated with diabetes 528
disorders 283
in diabetes 528
punch biopsy 338
Slit-lamp laser 330
Smartguard technology 766
Smooth muscle cells 634
carbonate 305
chloride 303
glucose 763
cotransporter-2, use of 439
myo-inositol co-transporter 402
potassium adenosine triphosphatase 402
serum 300
contraindications 651
efficacy 648
mechanism of action 647
pleiotropic benefits 649
posology 648
precautions 651
side effects 650
Solar ultraviolet B radiation 836
Solid organ transplantations 642
Somogyi effect 293
Specific cell membrane insulin receptors 510
Speech, disorganized 831
Sphingomyelin 210
Spina bifida 209
Spleen 778
Splenectomy 42
Splenic vein 200
Split-mix regimen 696
Stain-Masson's trichrome stain 54f
Standard height and weight chart 557t
Staphylococcal infections 424
Starch, nature of 561
Steatorrhea 200
Steatosis 515
major characteristics of 818
properties of 818
reaching lungs, major bulk of 821
types of 818
undifferentiated 53
Steroids 329
anti-inflammatory agents 499
discontinuation of 737
dose equivalents 736t
induced diabetes, management of 736
sparing regimen 818
tapering of 737
use of 736
Streptomyces bacteria 494
and diabetes 147
behavioral 148
chronic 149
diabetogenic 205
endocrine 148
hormone 297
cortisol 149
clinical implications of 743
pathogenesis of 743
transition in 732
management 151
osmotic 322
presence of 297
role of 148
test, low-risk 386
anterior circulation 399
epidemiology of 399
hemorrhagic 399
pathogenesis of 401b
pathophysiology of 400
posterior circulation 399
prevention of 403
volume 343
Stroma, fibrosed 817
Subcutaneous insulin
delivery, devices and techniques 674
infusion pump 8
protocols 306
role of 306
transition to 305
Substance use disorders, diagnosis of 827
Substantial cardiovascular disease 751
Succinyl-CoA 65
Sucrose 562
Sudden cardiac death 381
Sudomotor tests 347
Sukshma vyayama 581
Sulfonamides 636
adverse effects of 635
compounds, chemical structure of 633f
current positioning of 637
discovery 632
high dose of 278
mechanism of action of 633f
second generation 519
structure of 632
Superoxide production 144
Suppresses gluconeogenesis 75
Suprachiasmatic nuclei 134
Surrogate markers 485
Surya Namaskara 581
Sweat glands symptoms 338
Swelling, onset of 469
Swollen foot, unilateral 469
Sympathetic nervous system 575
Sympathetic system, assessment of 345
Syntax score 387
Systemic lupus erythematosus 276
T
Tachycardia 345
Tadalafil 539
Tamoxifen 516
Tarsometatarsal joints 469f
T-cell 90
abnormalities 92
islet reactive 179
lymphocytes, subset of 100
mediated autoimmune disease 92
Technetium diphosphonate bone 469
T-effector cells, activation of 89
Tegaserod, use of 506
Teneligliptin 643
Tenofovir 436
Teriparatide 486
Tetanus diphtheria and pertussis 457
Tetracycline 604
Tetrameric protein 61
Thermal insulation 475
Thermoregulatory sweat test 347
Thrombocytopenia 428
Thromboembolic events 309
Thyroid
abscess 440
diabetes 262
disease 262
disorders 275
prevalence of 262
dysfunction 264
diagnosis of 263
management of 264
underlying 264
hormone 44
effects of 129
replacement 258
peroxidase 275
Thyroiditis, chronic lymphocytic 94
Thyrotoxicosis 263
Thyrotropin-releasing hormone 191
Thyroxine 126
Tilt table testing 347
Tissue
breakdown 472
damage
chronic 467
hyperglycemia-induced 109
extrapancreatic 778
glycogen storage 205
peripheral 76
plasminogen activator 122
indications for 402
Titrate insulin therapy 680
Tolazamide 604
Touch perception, testing of 315
Toxic metabolites 255
Toxic multinodular goiters 262
Trabecular bone score 485
Tractional retinal detachment 331
Transcellular exudation 323
Transcription protein signaling pathway, activator of 248
Transplant, types of 49
Trauma, external 467
Trazodone 828
Tremors 229
Trialnet nutritional intervention 802
Trichophyton 531
Trifluoperazine 831
Triosephosphate dehydrogenase 73
Tris-hydroxymethyl-aminomethane 305
Trivalent inactivated influenza vaccine 454
Troglitazone 519
Trypsinogen pathway 196
and diabetes mellitus 429
causes of 429
diabetes interactions, immunology of 447
peculiarities of 431
severity 448
treatment of 447
Tubular dysfunction 753
Tubules, renal 80
Tumorigenicity, soluble suppression of 383
U
United Kingdom Department of Health 455
United States Diabetes Prevention Program 810
Universal Framework for Glycemic Control Strategy 768
University Group Diabetes Program 12
Urea cycle 116f
Uridine diphosphate glucose-glycogen glucosyltransferases 68
Urinary frequency 338
Urinary retention 348
Urine glucose measurement 42
Urine ketones 699
Urine microalbumin 359
Uronic acid pathway 67
Ursodeoxycholic acid 518
Utero-placental perfusion 221
V
Vaccinations, childhood 88
Vaccine, types of 454
Vaginal delivery 737
Vaginal dryness 338
Vagus nerve dysfunction 344
Valent conjugate vaccine 452
Valent polysacchari vaccine 452
Valine 121
Valproate 516
Valsalva test 345
Varenicline 831
Vascular bypass grafting 417
Vascular diseases 320
Vascular injury, underlying cause for 497
Vascular smooth muscle 634
Vascular thrombosis 775
Vasodilation, insulin induced 118
Venlafaxine 828
Ventricular septal defects 209
Vertebrobasilar obstruction 399
Vessel disease, large 34
Viagra 539
Vibration perception threshold testing 470
Victoza 761
Vildagliptin 762
Visible fats 564
Visual loss 320
Visual refractive changes 284
Vitamin 558
25-hydroxylase 836
B6 218
C 218
absorption 838
and beta-cell function 836
and diabetes 836
and gestational diabetes mellitus 838
and preparations 840
and systemic inflammation 838
binding protein 836
effects of 837
emerging role of 836
formulations 840
functions 837
insufficiency 430
major circulating form of 836
metabolite of 838
optimize 486
preparations, types of 840
receptors, expression of 836
D2 836
metabolite of 838
D3 836
metabolite of 838
E 517
K 11
malabsorption of fat soluble 258
Vulvovaginal pruritis 763